Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 901–963 of 963
Elbarbary, N. S., & Ismail, E. A. R. (2024) · Figshare · doi:10.6084/m9.figshare.24320090
Hafidh, K., & Abdella, N. (2022) · Figshare · doi:10.6084/m9.figshare.19101605
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12782637
Linn, W., Persson, M., Rathsman, B., Ludvigsson, J., Lind, M., Andersson Franko, M., & Nyström, T. (2023) · Figshare · doi:10.6084/m9.figshare.22623472
Self-citationNerpin, E., Toft, E., Fischier, J., Olinder, A. L., & Leksell, J. K. (2020) · Figshare · doi:10.6084/m9.figshare.12923291
Djupsjö, C., Kuhl, J., Andersson, T., Lundbäck, M., Holzmann, M. J., & Nyström, T. (2022) · Figshare · doi:10.6084/m9.figshare.21629313
Elbarbary, N. S., & Ismail, E. A. R. (2023) · Figshare · doi:10.6084/m9.figshare.24319951
Petria, I., ALBUQUERQUE, S., Varoquaux, G. P., Vie, J.-J., Venteclef, N., Mohammedi, K., Roussel, R., Camoin, M., Perseghin, G., Velho, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21582085
Stephen, D., Nordin, A., Nilsson, J., & Persenius, M. W. (2022) · Figshare · doi:10.6084/m9.figshare.19881500
Giménez‐Pérez, G., Viñals, C., Mata-Cases, M., Vlacho, B., Real, J., Franch‐Nadal, J., Ortega, E., & Mauricio, D. (2024) · Figshare · doi:10.6084/m9.figshare.26604307
Stephen, D., Nordin, A., Nilsson, J., & Persenius, M. W. (2022) · Figshare · doi:10.6084/m9.figshare.19881506
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12782628
Biasio, M. J. D., Furman, M., Clarke, A. B. M., Hui, W., Elia, Y. T., Baranger, J., Villemain, O., Mertens, L., & Mahmud, F. H. (2024) · Figshare · doi:10.6084/m9.figshare.26725424
Sanchez, M., Kannengiesser, C., Hoang, S., Potier, L., Fumeron, F., Venteclef, N., Scheen, A. J., Gautier, J., Hadjadj, S., Marre, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21316169
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12782634
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12782640
Stephen, D., Nordin, A., Nilsson, J., & Persenius, M. W. (2022) · Figshare · doi:10.6084/m9.figshare.19881509
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12782622
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12782631
Nerpin, E., Toft, E., Fischier, J., Olinder, A. L., & Leksell, J. K. (2020) · Figshare · doi:10.6084/m9.figshare.12923294
Toyoshima, M. T. K., Santana, M. F. M., da Silva, A. R. M., Mello, G. B., Santos‐Bezerra, D. P., Góes, M. F. S., Bosco, A., Caramelli, B., Ronsein, G. E., Corrêa‐Giannella, M. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26574391
Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes
Fava, D., Saltik, A. Z. O., Pollock, R. F., Tucker, M., Buompensiere, M. I., de Portu, S., & Lambadiari, V. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251408099
Khairani, P., Rini, E. A., Pabuti, A., Masnadi, N. R., Nurdin, A., & Lestari, R. (2026) · International Journal of Research and Review · doi:10.52403/ijrr.20260206
Beverloo, C. Y. Y., Ibrahim, S., Nurmohamed, N. S., Snethlage, C. M. F., Koning, M., Murphy, A. J., Serné, E. H., Planken, R. N., Nieuwdorp, M., Stroes, E. S. G., et al. (2026) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-026-03640-w
Swetha, P., Chaganti, K. R., Sasikala, C., Srinu, N., Rao, P. V., & Ahmed, M. Z. (2025) · International Conference on Intelligent Computing, Information and Control Systems (ICOIICS) · doi:10.1109/icoiics67115.2025.11390437
“…learning in healthcare continues to be adopted, tree-based machine learning models, including Random Forest (RF) and Gradient Boosting Machines (GBMs), have become highly popular due to their strength, non-linear relationships, and great generalization in the case of heterogeneous data [3], [4].”
Evidencia científica actual sobre el impacto de la diabetes tipo 1 en población infantil
Martín, R. A. (2026) · Enfermería en cardiología: revista científica e informativa de la Asociación Española de Enfermería en Cardiología · doi:10.59322/93.6981.iu2
Type 1 Diabetes: Pathophysiology and Treatment Considerations for Cardiovascular Risk and Disease
Tommerdahl, K. L., & Bjornstad, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00005-7
Welters, A., Reinauer, C., Schwab, K. O., Boettcher, C., Hess, M., Bartelt, H., Dost, A., Rosenbauer, J., Galler, A., & Holl, R. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70610 · Cited by 1
“…threshold of 7.0% (53 mmol/mol) are associated with at least a twofold increased risk of death from any cause or from cardiovascular causes [10], recent large-scale epidemiological studies suggest that cardiometabolic risk factors, such as poor glycaemic con-trol, hypertension,…”
InfluentialWeiskorn, J., Becker, M., Kamrath, C., Hammersen, J. E., Pozza, S. B., Müller‐Roßberg, E., Holder, M., Burckhardt, M., & Holl, R. W. (2026) · Diabetes Care · doi:10.2337/dc25-2459
Akbar, M. N., Smith, T. J., Chinnarasu, S., Welch, W., Zuofei, W., Litts, B., LeStourgeon, L. M., Saleem, M., Khan, M. M., Kirabo, A., et al. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00276-6
Clinical Implications and Applicability of Time in Tight Range
Jin, S. (2026) · Journal of Korean Diabetes · doi:10.4093/jkd.2026.27.1.5
Altered small dense LDL profiles in long-standing controlled type 1 diabetes
Sardà, H., Solé, A., Colom, C., Borràs, C., Carreras, G., Benítez, S., Miñambres, I., Escolá‐Gil, J. C., Sánchez‐Quesada, J. L., & Pérez, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1804987
Popovic, D. S., Κender, Ζ., & Koufakis, T. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70226
“Moreover, the risk of all-cause and cardiovascular mortality remains significantly elevated compared with the general population, even among those achieving optimal glycaemic control [3].”
Cardiovascular Disease and Dyslipidemia in Pediatric Type 1 Diabetes
Kim, G. K., Brar, P. C., & Bansal, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01409-z · Cited by 1
“Based on CVD risk prediction scores, the strongest risk predictors for CVD in T1D include hyperglycemia, hypertension, dyslipidemia, diabetic kidney disease, insulin resistance, and obesity [4, 12, 31–35].”
Schweiger, D. Š., Mlinarič, Z., Macedoni, M., Giani, E., Plesnik, E., Hovnik, T., Kotnik, P., Dovč, K., Bratina, N., Battelino, T., et al. (2026) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2026.108391
Current State of Cardiorenal Disease in People with Type 1 Diabetes
Fernandes, S., Hettinger, B., Ang, L. P., & Pop‐Busui, R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.004
Basu, S., Zafra‐Tanaka, J. H., & Beran, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00002-1
Accelerated hematopoietic aging in type 1 diabetes links telomere attrition to myocardial infarctionPreprint
Xu, Z., Jiang, H., Admassu, T., Yeung, S., Roy, S., Ruffing, C., Shanguhyia, M., Syeda, Z. A., & Alagpulinsa, D. A. (2026) · medRxiv · doi:10.64898/2026.05.13.26353138
Ambalavanan, J., Bhasin, K., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.013
Fernandes, S., Hettinger, B., Ang, L. P., & Pop‐Busui, R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.007
Liu, C., Renström, F., Gastaldi, G., Brändle, M., & Bilz, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1819019
“Although tight glycemic control improves cardiovascular outcomes (8), data from the Swedish diabetes registry show a twofold increased risk in patients with well-controlled T1DM compared to the general population (2).”
Dario, P. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261455365 · Cited by 1
Faivre, M., Gouzi, F., Ayoub, B., Myzia, J., Villard, O., Suc, A., Hayot, M., Roubille, F., Dauvilliers, Y. A., Thireau, J., et al. (2026) · Physiological Reports · doi:10.14814/phy2.70951
“Indeed, even in patients who achieve a strict glycemic control at target, the risk of CVD remains approximately twice as high (Lind et al., 2014).”
Giménez, M., Bellido, V., Quirós, C., Conget, I., Herguido, N. G., Roca, D., Pérez-Morales, A., van den Heuvel, T. R. A., Juachon, M. J., & Petrovski, G. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01878-0
Lambadiari, V., Tentolouris, N., Vazeou, A., Christoforidis, A., Kanaka‐Gantenbein, C., Makrilakis, K., Didangelos, T., Juachon, M. J., Smaniotto, V., van den Heuvel, T. R. A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01883-3 · Cited by 1
Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?
Rodrigues, F., White, M., & O’Connell, M. A. (2026) · Diabetic Medicine · doi:10.1111/dme.70382
Horton, W. B., Anderson, K. C., Love, K. M., Jahn, L. A., Hartline, L. M., Patrie, J. T., Liu, J., Solga, M. D., Awan, W. J., Thakur, A., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06806-2
Trajectory of Kidney Function in T1D over Time: A Scoping Review
CO, F., Whitlock, R. H., Katta, A., Aldworth, C., Mares, J. W., Zheng, Z., Ferri, M. B., Askin, N., & Tangri, N. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01899-9
Zhou, J., Mychaleckyj, J. C., Haddad, F., Costacou, T., Orchard, T. J., & Miller, R. G. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03313-x
Serafin, A., Kołodziej, A., Skalska, M., Wojtachnio, N., Strzyż, J., Rymska, K., & Starczyk, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5362
Toxic crossroads: environmental pesticides and their endocrine footprints in global metabolic health
Onikanni, S. A., Murucci, M. D., da Costa, T. G., Amos, O. E., Ajayi, O. D., Dao, T., Ajiboye, B. O., Adewole, E., Piperni, S. G., & Miranda‐Alves, L. (2026) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0183
Li, Y., Song, J., Liu, L., Li, W., & Wang, Q. (2026) · International Journal of Endocrinology · doi:10.1155/ije/5683927
Miranda‐Martinez, L., Niznik, C. M., Yee, L. M., & Fisher, S. A. (2026) · Pregnancy · doi:10.1002/pmf2.70388
Yoon, J., Kim, J., Park, S., & Kim, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1938241
Mathiesen, D. S., Hansen, J. V., Nabe-Nielsen, M. I., Høck, A., Nielsen, C. K., Pedersen, M. G., Kristensen, P. L., Andersen, H. U., Aarestrup, M. L., Forman, J. L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10972198/v1
Kim, J. A., Choi, J., Kim, K. J., Shin, S. M., Kim, Y.-E., Kim, K. J., Kim, H. Y., Kim, N. H., & Kim, S. G. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70457
Varga, B., Nemes-Nagy, E., Aszalos, C., Abalasei, B. L., Szabó, M. I. M., & Tilinca, M. C. (2026) · Diabetology · doi:10.3390/diabetology7100198
Amer, B., Alnukhali, M., Haidarah, A., & Ahmad, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845336
Maladie cardiovasculaire et diabète de type 1 : données épidémiologiques et physiopathologiques
Vergès, B. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.10.006
Tocilizumab (TCZ) in New-onset Type 1 Diabetes (ITN058AI)
Md, C. G., & Bucker, J. (2023) · ImmPort · doi:10.21430/m3bjt9805b
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.